Table 2.
Biomarker characteristics in CIN+ and CIN− participants at various time points.
| Variable | CIN+ (n = 30) | CIN− (n = 60) | p value |
|---|---|---|---|
| sNGAL_p (ng/ml) | 100.31 (64.28–142.01) | 74.33 (43.97–127.99) | 0.34 |
| sNGAL_24 (ng/ml) | 99.61 (72.26–135.98) | 78.42 (51.12–107.00) | 0.07 |
| sNGAL_48 (ng/ml) | 83.81 (57.90–109.05) | 60.91 (37.36–100.71) | 0.13 |
| sNGAL_5 (ng/ml) | 96.20 (74.48–156.66) | 65.77 (51.94–72.44) | 0.06 |
| uNGAL_p (ng/ml) | 88.4 (39.3–366.2) | 34.1 (17.2–62.2) | 0.02 |
| uNGAL_24 (ng/ml) | 40.1 (33.1–96.9) | 46.5 (28.5–100.6) | 0.72 |
| uNGAL_48 (ng/ml) | 39.4 (22.1–100.9) | 49.5 (14.2–98.3) | 0.96 |
| sCystatin C_ p (ng/ml) | 711.45 (550.08–934.10) | 687.41 (566.61–769.76) | 0.25 |
| sCystatin C_24 (ng/ml) | 856.59 (620.75–1002.96) | 617.42 (533.11–805.20) | <0.01 |
| sCystatin C_48 (ng/ml) | 764.32 (560.28–1010.71) | 572.13 (461.67–708.11) | 0.01 |
| sCystatin C_5 (ng/ml) | 811.52 (708.54–986.12) | 596.14 (534.56–684.38) | 0.01 |
| uCystatin C_p (ng/ml) | 53.7 (32.0–412.1) | 49.4 (13.6–170.0) | 0.38 |
| uCystatin C_24 (ng/ml) | 107.8 (64.3–157.7) | 95.9 (27.0–193.9) | 0.82 |
| uCystatin C_48 (ng/ml) | 47.8 (16.6–166.8) | 43.5 (17.7–132.5) | 0.87 |
| sIL18_p (pg/ml) | 170.41 (105.19–327.4) | 123.73 (65.87–178.2) | 0.13 |
| sIL18_24 (pg/ml) | 152.32 (92.905–279.62) | 122.36 (82.45–256.6) | 0.40 |
| sIL18_48 (pg/ml) | 137.62 (100.965–285.14) | 95.75 (73–165.59) | 0.06 |
| sIL18_5 (pg/ml) | 133.385 (122.36–395.75) | 131.93 (70.82–294.91) | 0.64 |
| uIL18_p (pg/ml) | 102.8 (55.3–185.6) | 76.8 (33.2–189.0) | 0.38 |
| uIL18_24 (pg/ml) | 145.1 (22.6–326.2) | 131.0 (50.7–262.4) | 0.97 |
| uIL18_48 (pg/ml) | 125.1 (50.2–348.7) | 124.6 (57.0–372.6) | 0.92 |
| sβ2M_p (μg/ml) | 4.4 (3.8–7.8) | 3.8 (3.2–4.9) | 0.04 |
| sβ2M_24 (μg/ml) | 4.55 (3.9–7.55) | 3.7 (2.9–4.8) | 0.01 |
| sβ2M_48 (μg/ml) | 5.1 (3.8–6.9) | 3.3 (2.7–4.5) | <0.001 |
| sβ2M_5 (μg/ml) | 12.1 (4.4–16.4) | 3.7 (3.1–4.9) | 0.01 |
| sTNFα_p (pg/ml) | 4.87 (4.15–9.12) | 4.6 (2.65–5.95) | 0.12 |
| sTNFα_24 (pg/ml) | 5.3 (4.15–6.7) | 5.23 (3.43–7.39) | 0.94 |
| sTNFα_48 (pg/ml) | 5.9 (4.6–6.7) | 4.29 (2.6–7.04) | 0.06 |
| sTNFα_5 (pg/ml) | 4.3 (3.43–5.23) | 6.315 (4.26–8.26) | 0.22 |
| sIL10_p (pg/ml) | 4.94 (4.5–11.3) | 4.1 (2.59–5.4) | 0.19 |
| sIL10_24 (pg/ml) | 4 (3.4–5.5) | 3.9 (2.6–5) | 0.45 |
| sIL10_48 (pg/ml) | 4.6 (3.7–9.2) | 3.4 (2–4.5) | 0.10 |
| sIL10_5 (pg/ml) | 9.5 (9.5–9.5) | 4.2 (3.24–19.4) | 0.51 |
| uKIM_p (pg/ml) | 108.1 (39.9–1593.2) | 39.9 (12.2–274.6) | 0.21 |
| uKIM_24 (pg/ml) | 144.0 (39.9–1343.0) | 91.6 (12.2–196.8) | 0.26 |
| uKIM_48 (pg/ml) | 160.2 (45.8–303.5) | 91.6 (12.2–274.5) | 0.34 |
CIN−, CIN absent; CIN+, CIN present; sNGAL and uNGAL, serum and urine neutrophil gelatinase-associated lipocalin; sIL18 and uIL18, serum urine interleukin 18; sβ2M, serum beta 2 microglobulin; sTNFα, serum tumour necrosis factor alpha; uKIM1, urine kidney injury molecule 1 at various time points.